Genitourinary Cancer and GU Cancers 2021

The GU Cancer Channel on VJOncology is supported by Exelixis These supporters have no influence over the production of the content.

1:50
Current treatment landscape of seminoma
Siamak Daneshmand • 18 Feb 2021
3:05
CA 125, CA19-9 and CEA: tumor markers in bladder cancer
Siamak Daneshmand • 18 Feb 2021
3:18
SEMS: surgery as first-line therapy for seminoma
Siamak Daneshmand • 18 Feb 2021
3:43
The history of biomarkers in the treatment of prostate cancer
Howard Scher • 18 Feb 2021
3:56
CTC enumeration as a prognostic biomarker in prostate cancer
Howard Scher • 18 Feb 2021
8:53
Prognostic biomarkers to guide treatment of mCRPC
Howard Scher • 18 Feb 2021
1:53
Factors impacting response to ICIs in mUC
Shilpa Gupta • 17 Feb 2021
5:30
Angiogenic and T-effector subgroups and propensity for PBRM1 and BAP1 alterations in ccRCC
Pedro Barata • 16 Feb 2021
5:30
Clinical outcomes and genomic correlates of African Americans with mCSPC
Pedro Barata • 16 Feb 2021
3:38
OS of patients with mCRPC with PTEN loss-of-function identified by genomic profiling
Shilpa Gupta • 17 Feb 2021
1:49
The impact of antibiotic use on ICI treatment in mUC
Shilpa Gupta • 17 Feb 2021
2:15
Highlights in urothelial cancer for ASCO GU 2021
Shilpa Gupta • 17 Feb 2021
6:05
Using the polygenic risk score for targeted prostate cancer screening
Jana McHugh • 15 Feb 2021
1:29
Emerging treatment options for patients with prostate cancer
Jana McHugh • 15 Feb 2021
4:44
VEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancer
Tian Zhang • 17 Feb 2021
2:29
Assessing the impact of ADT in patients with prostate cancer and COVID-19
Tian Zhang • 17 Feb 2021

The GU Cancer Channel on VJOncology is supported by Exelixis

These supporters have no influence over the production of the content.

The content of VJOncology is intended for healthcare professionals